A blast from the recent past. BoM2 just seems like low hanging fruit, given the cornucopia of findings from BoM und the resulting BTD from the FDA. Heck, BoM might have even achieved end points with just a little more power. The reality is that apabetalone and epigenetics is so new (and maybe weird?) to conventional thinking that it takes time to learn and refine the proper understandings and approach, and as we have learned as investors this is also true of ideal clinically/scholastically "provable" end points. Failed studies cabn potentially and contunually prove direction when obviously good data is still gleaned even from "failed" studies along the way, which seems to be the case with apabetalone.

Old news but worth the reminder:

https://old.firstwordpharma.com/node/1734522

Now flash forward to Covid trials. Quicker path to approval potentially based on simpler and shorter trials, and emergent care needs. 

Even more safety data accumulations in yet other scenarios and conditions, and SOC drug combinations.

Hopefully and potentially: Building an almost unimpeachable safety profile. And benefits profile whther study end points have been reached or not.

At what point does the overall "equity" and value of apabetalone reach critical mass with regulators?

Let's say apabetalone gets good Covid data and achieves emergency relief indications in Canada later this year, and PIII yields good results in the U.S. afterward and makes it to market. Couple this with more ongoing safety data, and demostrable secondary improvements in these Covid patients for diabetic/cardio/renal/cognitive/PAH positive improvement data and BTD ... now for a drug that has actually and finally APPROVED as "safe and effective" for an important and significant indication (Covid).

Think about the valuation potential. Think about the somewhat remote possibility of emergency relief for indication in other conditions for which apabetalone has shown safety and significant benefit despite narrowly missed primary end points? You can't "un-see" the good data.

I know I am all over the place, but my point is that Covid may well be huge by itself with good news, but potentially also the key to unlocking other key doors more quickly given the types of patients (that we have studies and know well) that will have much higher risks with Covid, and may want to stay on apabetalone longer.

I mean what do you do if a patient with diabetic cardiopathy and renal issues shows significant improvement in those other vital areas since beginning on a drug for Covid that has also shown safety and benefit for those conditions also?

Apabetalone-Covid could prove to have great benefit for RVX investors and patients, and be the ticket to the show finally ... but it could also come with "back stage passes" for other important things.